These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6681233)

  • 1. Middle molecules evaluation in chronic renal failure during conservative treatment.
    Severini G; Carta S; Taccone-Gallucci M; Mazzarella V; Iacona A; Meloni C; Casciani CU
    Ann Ist Super Sanita; 1983; 19(2-3):417-9. PubMed ID: 6681233
    [No Abstract]   [Full Text] [Related]  

  • 2. [Middle molecule level and myocardial contractility in kidney patients].
    Dimitrakov D; Pisanets M
    Vutr Boles; 1986; 25(2):18-20. PubMed ID: 3716372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation between middle molecules and parathyroid hormone in patients with chronic renal failure.
    Fröhling PT; Kokot F; Cernacek P; Vetter K; Kuska J; Spustova V; Kaschube I; Dzurik R
    Miner Electrolyte Metab; 1982 Jan; 7(1):48-53. PubMed ID: 7169976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Middle molecules--formation and methods of determination].
    Nikolaĭchik VV; Kirkovskiĭ VV; Moin VM; Lobacheva GA; Mazur LI; Bychko GN
    Lab Delo; 1989; (8):31-3. PubMed ID: 2477623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New biological method for determination of the desintoxication rate of human plasma after dialysis.
    Kovatchev D; Dimitrov H; Hristova P; Nenov D
    Life Support Syst; 1983; 1 Suppl 1():191-4. PubMed ID: 6336408
    [No Abstract]   [Full Text] [Related]  

  • 6. [The evaluation of the efficacy of efferent therapy in patients with acute and chronic kidney failure by the spectrum of blood middle-molecule fractions].
    Kon'kova TA; Chudnovskaia MV; Golovanov SA
    Urol Nefrol (Mosk); 1994; (4):35-7. PubMed ID: 7985299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between plasma concentration of middle molecular weight fraction b, motor nerve conduction velocity, and plasma creatinine in experimental chronic renal failure rats.
    Boudet J; Man NK; Cueille G; Legrain Y; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():115-8. PubMed ID: 7295077
    [No Abstract]   [Full Text] [Related]  

  • 8. [Middle molecules as uremic toxins (status of the problem)].
    Gudim VI; Gabriélian NI
    Lab Delo; 1985; (3):145-51. PubMed ID: 2581043
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies on serum middle molecules in chronic renal failure--a preliminary report.
    Shieh SD; Tschai HJ; Huang HW; Chang GG
    Taiwan Yi Xue Hui Za Zhi; 1984 Apr; 83(4):347-51. PubMed ID: 6589355
    [No Abstract]   [Full Text] [Related]  

  • 10. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
    Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program].
    Mydlík M; Dzúrik R; Derzsiová K; Spustová V
    Cas Lek Cesk; 1983 Dec; 122(51):1573-6. PubMed ID: 6652672
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of an oral sorbent (AST-120) on the clinical course of uremic peak 2a in chronic renal failure].
    Koide K; Toyama J; Inoue N; Koshikawa S; Akizawa T; Takahashi K; Hidaka S; Yamane Y; Nakao M; Ono S
    Nihon Jinzo Gakkai Shi; 1987 Aug; 29(8):1003-11. PubMed ID: 3694879
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythrocyte transport of middle molecular substances.
    Gajdos M; Spustová V; Geryková M; Dzúrik R
    Proc Eur Dial Transplant Assoc; 1981; 18():183-7. PubMed ID: 7329966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Can the concentration of middle molecular substances in plasma contribute to the assessment of the adequacy of regular dialysis therapy?].
    Válek A; Spustová V; Lopot F; Erben J; Dzúrik R
    Cas Lek Cesk; 1984 May; 123(20):599-604. PubMed ID: 6467309
    [No Abstract]   [Full Text] [Related]  

  • 15. [Diagnostic value of determining middle molecules in the blood plasma in nephrological diseases].
    Gabriélian NI; Dmitriev AA; Kulakov GP; Melikian AM; Shcherbaneva OI
    Klin Med (Mosk); 1981 Oct; 59(10):38-42. PubMed ID: 7311409
    [No Abstract]   [Full Text] [Related]  

  • 16. Middle molecules in patients with pre-dialysis chronic renal failure: a comparative clearance study.
    Schindhelm K; Lustenberger N; Nordmeyer C; Farrell P; Stolte H
    Clin Nephrol; 1982 Apr; 17(4):200-5. PubMed ID: 7075036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Uremic toxins. Chromatographic profiles of substances of low and medium molecular weight].
    Nesse AB; Arrizurieta de Muchnik E
    Medicina (B Aires); 1984; 44(2):117-26. PubMed ID: 6537452
    [No Abstract]   [Full Text] [Related]  

  • 18. [Platelet aggregation in patients with chronic renal insufficiency not under dialytic treatment].
    Camici M; Evangelisti L; Balestri PL
    Minerva Nefrol; 1981; 28(4):467-70. PubMed ID: 7339515
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal handling of middle molecules in uremic patients and in the isolated rat kidney.
    Lustenberger N; Schindhelm K; Nordmeyer C; Schurek HJ; Stolte H
    Artif Organs; 1981; 4 Suppl():110-4. PubMed ID: 7295076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uremic middle molecules. Accumulation, renal excretion and elimination by extra-corporeal treatment.
    Asaba H
    Scand J Urol Nephrol Suppl; 1982; 67():1-65. PubMed ID: 6761857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.